H3K27me3 demethylase KDM6B promotes IGFBP5 expression which leads to epigenetically induced resistance to PI3K inhibiters. Combination therapy targeting KDM6B and PI3K results in cancer cell apoptosis by downregulating IGFBP5. Here, KDM6B is linked to cancer.